4CMenB tied to modest gonorrhea protection in real-world study
The 38.4% reduction in gonorrhea risk “could translate into preventing a substantial number of infections and complications.”
-
By
-
Julia Cipriano, MS, CMPP
-
September 9, 2026
-
-
1
The 4CMenB vaccine was associated with 38.4% effectiveness against gonorrhea among adolescents in a high-prevalence setting.
-
2
The study involved 30,650 adolescents, with 9.6% fully vaccinated and 42.4% identifying as Aboriginal or Torres Strait Islander.
-
3
Meningococcal carriage increased from 4% to 6.2%, driven by genogroup B and nongroupable strains, while disease-associated carriage remained stable.
-
4
Limitations included lower-than-expected vaccine uptake and missing data, impacting the robustness of the findings.
-
5
4CMenB should complement, not replace, existing gonorrhea prevention strategies, and further randomized studies are needed to explore its efficacy.
